Polypoidal choroidal vasculopathy (PCV), an oddity shown at fluorescein conferences 35 years ago, is now recognized as a common cause of neovascular maculopathy among those older than 50 years.1 Its prevalence has not increased, but new imaging techniques have revealed its features and ophthalmic consciousness has been raised. Randomized clinical trials that compare treatments, rather than case series, are now feasible.
Browning DJ. Adopting the Results of Everest II Into Practice: A Clearer View From a Higher Level Study. JAMA Ophthalmol. 2017;135(11):1214–1215. doi:10.1001/jamaophthalmol.2017.3118
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: